Articles On Pharmaxis (ASX:PXS)

Title Source Codes Date
Pharmaxis doses first patient in phase 2 bone marrow cancer trial

Clinical stage drug development company Pharmaxis (ASX:PXS) has commenced dosing in the phase 2 clinical trial studying its investigative PXS-5505 in patients with the bone marrow cancer myelofibrosis.

BiotechDispatch PXS 5 days ago
Pharmaxis embarks on phase two bone marrow cancer trial

Bone marrow cancer affects one in 100,000 people, but Pharmaxis’ lead asset could one day help treat patients with this condition.

Proactive Investors PXS 5 days ago
Closing Bell: Investors dine out on yellowcake as the ASX trades flat

The ASX 200 was unable to break free from its recent shackles, edging lower by 0.11% in the Wednesday session. But as a measure of a little more risk-on sentiment creeping back into markets, the microcap Emerging Markets index comfortably o...

Stockhead PXS 6 days ago
Pharmaxis cleared to progress to Phase 2 Bone marrow cancer trial

“We are very pleased to have completed the dose-escalation phase of this study with such clear and positive findings,” Pharmaxis CEO Gary Phillips said.

Proactive Investors PXS 2 weeks ago
ASX Health Stocks: Pharmaxis progresses to Phase 2 study on bone marrow cancer

The ASX 200 health stocks index (XHJ) is falling by 0.55% at the time of writing, compared to the broader ASX 200 index which fell by 0.50%. Fibrotic and inflammatory diseases-focused biotech, Pharmaxis (ASX:PXS), has just announced further...

Stockhead PXS 2 weeks ago
Pharmaxis welcomes green light to progress to Phase 2 bone marrow cancer trial

Proactive Investors PXS 2 weeks ago
Pharmaxis cleared to progress to phase 2 bone marrow cancer trial

Pharmaxis (ASX:PXS) has announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with bone marrow cancer myelofibrosis for 28 days at three dosage levels. ...

BiotechDispatch PXS 2 weeks ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead PXS 1 month ago
Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

Topical treatment safe and well tolerated in study of healthy volunteers Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic exposure Collaboration with research team led by Professor Fiona Wood AM planning fo...

FNArena PXS 1 month ago
Pharmaxis’ treatment to prevent wound and burns scars clears phase1 trial

“We will be investigating the safety of 3 months’ treatment with PXS‐6302, and exploring if 3 months’ treatment with PXS‐6302, at a dose that we now know will significantly inhibit an enzyme implicated in scar formation, can make a differen...

Proactive Investors PXS 1 month ago
ASX Health Stocks: Beamtree gets on the M&A trail while Creso Pharma eyes NASDAQ listing

Top of the ASX health stocks today is Creso Pharma (ASX:CPH), which rose more than 10% after announcing plans to pursue a NASDAQ and ASX dual listing. The news follows a mutual termination of its proposed merger with Red Light Holland Corp....

Stockhead PXS 1 month ago
Pharmaxis hails positive results in Phase 1 scarring trial

Proactive Investors PXS 1 month ago
Pharmaxis wound and scar treatment clears phase one trial

Pharmaxis (ASX:PXS) has announced that its novel topical drug treatment for scarring has delivered positive phase one clinical trial results and will now advance to the next stage of development in patients.

BiotechDispatch PXS 1 month ago
ScoPo’s Powerplays: Quality names continue to catch a bid as earnings roll in

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Stockhead PXS 1 month ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead PXS 2 months ago
Pharmaxis enters $2.5 million agreement for rights to Orbital inhaler

Pharmaxis will receive an upfront US$250,000 payment for the 12‐month option and a further US$2.5 million if Aptar decides to exercise the option. In doing so, it will also pay Pharmaxis industry standard royalties on income received for Or...

Proactive Investors PXS 2 months ago
Here’s why AVITA Medical, Pharmaxis and Telix shares are trending today

Highlights AVITA Medical disclosed that the US Food and Drug Administration (FDA) has authorised its request to amend the RECELL® System pivotal trial. Pharmaxis has granted Aptar Pharma an exclusive 12-month option for developing and...

Kalkine Media PXS 2 months ago
Pharmaxis grants option deal with Aptar Pharma to acquire its proprietary inhaler Orbital

Proactive Investors PXS 2 months ago
Market highlights and 5 ASX small caps to watch on Tuesday

Global markets stay cool US stocks edged higher overnight to post their fifth straight day of gains, as attention centred around geo-political concerns following the US withdrawal from Afghanistan. The Dow Jones rose by 0.31%, and the S&am...

Stockhead PXS 2 months ago
Pharmaxis updates on bone marrow cancer trial and talks potential of PXS-5505 in liver cancer

Proactive Investors PXS 2 months ago
Why Latitude Group and Telstra created a buzz on the ASX today?

Summary  Latitude Group Holdings has cracked a deal for fintech Symple to accelerate business growth. Telstra Health has signed a pact to acquire MedicalDirector to support its vision of becoming a leading partner to the healthcare sec...

Kalkine Media PXS 2 months ago
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

DATA PRESENTED FROM COLLABORATION OF PHARMAXIS AND UNIVERSITY OF ROCHESTER MEDICAL CENTER AT US SCIENTIFIC MEETING COMBINATION OF PXS-5505 AND STANDARD OF CARE DEMONSTRATES A NOVEL THERAPEUTIC STRATEGY FOR LIVER CANCER SYDNEY, Aug. 5, 2021...

FNArena PXS 2 months ago
Which stocks trended the most today?

The S&P/ASX200 closed up Thursday, gaining 7.90 points or 0.11% to 7,511.10 and setting a new 100-day high. The top performing stocks in this index were NIB Holdings Limited (ASX:NHF)  Nuix Limited (ASX:NXL), up 3.05% and 2.75% respecti...

Kalkine Media PXS 2 months ago
ASX ends at fresh record high; BHP, Rio, Fortescue decline

Summary Benchmark index, the ASX200, rose 0.1% to hit a fresh closing high of 7,511. Eight of the 11 sectors ended in green, while consumer discretionary and A-REIT gained the most. Health insurance firm NIB Holdings topped the gainer...

Kalkine Media PXS 2 months ago
Why are Emyria, Pharmaxis, Immutep, and Neuren trending today?

Summary Emyria has signed a deal with the University of Western Australia (UWA) to develop a novel psychedelics pipeline. Pharmaxis’ anticancer drug PXS-5505 shows positive results in the pre-clinical liver cancer model. Immutep updat...

Kalkine Media PXS 2 months ago
ASX health stocks: dorsaVi leads the pack with 12% jump on major contract extension

ASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which rose by 0.11%. Micro cap medical device company dorsaVi (ASX:DVL) took the limelight this morning, jumping by 12% after saying that it has ext...

Stockhead PXS 2 months ago
Pharmaxis welcomes data presented by University of Rochester showing PXS-5505 decreases tumour burden in pre-clinical liver cancer model

A research team at the University of Rochester Medical Center in New York State has been investigating the role of lysyl oxidase enzymes in liver cancer and whether PXS-5505 can improve the efficacy of current chemotherapy drugs by inhibiti...

Proactive Investors PXS 2 months ago
Presentation of pre-clinical data for Pharmaxis liver cancer candidate

Pharmaxis (ASX:PXS) has announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma.

BiotechDispatch PXS 2 months ago
Market Highlights and 5 ASX Small Caps to watch on Thursday

Wall Street mixed on Fed’s statement US stock markets were mixed overnight, after the US Fed Vice Chair said he anticipates rates to increase by 2023. “Given this outlook and so long as inflation expectations remain well anchored at the 2%...

Stockhead PXS 2 months ago
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead PXS 2 months ago
Hottest stocks on the ASX today

Summary REA Group (ASX:REA) completes transaction with PropertyGuru BNK Banking (ASX:BBC) announces alliance with Goldman Sachs for A$500m Securitisation Warehouse Westpac (ASX:WBC) to kick-off jab program for Western Sydney The S...

Kalkine Media PXS 2 months ago
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead PXS 2 months ago
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Stockhead PXS 3 months ago
ScoPo’s Powerplays: ‘Go long equities’ as Nanosonics, Antisense, Volpara to benefit from V-shaped recovery

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

Stockhead PXS 3 months ago
Last Orders: ASX begins FY22 down 0.65 per cent

It wasn’t a happy start to the new financial year for Australia’s bourse, which lost nearly two thirds of one per cent today. Likewise, the ASX200, which rose 22% in FY21, closed down 0.65% to 7,266. Meanwhile, the ASX Emerging Companies In...

Stockhead PXS 3 months ago
Pharmaxis sells Australian distribution rights for Bronchitol and Aridol for A$2 million

Under the agreement, BTC Health will acquire marketing authorisations for both products in Australia, New Zealand, Singapore, Malaysia and Hong Kong.

Proactive Investors PXS 3 months ago
Pharmaxis announces first results in cancer trial and sells rights to key products

Australian company Pharmaxis (ASX:PXS) has announced results of data analysis from the first of three stages in its phase one trial studying a potential new treatment for the bone marrow cancer myelofibrosis and announced the sale o...

BiotechDispatch PXS 3 months ago
Pharmaxis encouraged by first results in bone marrow cancer trial

Proactive Investors PXS 3 months ago
Pharmaxis’ first results in bone marrow cancer trial show strong inhibition of target enzymes

The second dose cohort of the clinical trial is fully recruited and dosing of all patients has commenced at participating sites in Australian and South Korean hospitals.

Proactive Investors PXS 3 months ago
Why are these ASX penny stocks making the headlines today?

Summary The OVT share price has risen by 50% to AU$0.003 in today’s session, clocking a volume of over 30.7 million shares. Amid a trading update and FY21 guidance update, the GTN share price surged to AU$0.41, an increase of 28.1%. P...

Kalkine Media PXS 3 months ago
Pharmaxis progresses clinical trial in bone marrow cancer

The company’s PXS-5505 multinational trial in Myelofibrosis has been cleared by the safety committee to advance to the second stage of Dose escalation study.

Proactive Investors PXS 4 months ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead PXS 4 months ago
Pharmaxis drug to be focus of new brain cancer study with grant from Charlie Teo Foundation

Proactive Investors PXS 5 months ago
Australian drug discovery to be studied in the US

A drug candidate discovered by the Australian company Pharmaxis (ASX:PXS) will be the focus of a new trial aimed at studying its potential as a treatment for an aggressive and deadly form of brain cancer.

BiotechDispatch PXS 5 months ago
Here’s why Pharmaxis (ASX:PXS) shares are trending on the ASX

Summary Pharmaxis Ltd and Charlie Teo Foundation have identified a new drug that shows promise in tackling a deadly form of brain cancer. Pharmaxis’ PXS-5505 will be a part of preclinical testing to assess its efficacy for glioblastoma...

Kalkine Media PXS 5 months ago
Charlie Teo Foundation grant to fund key research of new Pharmaxis drug to tackle brain cancer

PXS-5505 will enter pre-clinical efficacy testing for glioblastoma, the most common form of brain cancer with an average survival of only 15 months from diagnosis.

Proactive Investors PXS 5 months ago
Capital Raisings Recap: Nearly $10 billion has already been raised in 2021

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Stockhead PXS 5 months ago
ResMed (ASX:RMD) shares fall after reporting flat sales in Q3 FY21

Summary Digital health behemoth ResMed has released its quarterly results for the March 2021 quarter reporting flat sales. The Company witnessed lower device sales and decreased demand for its ventilators due to COVID-19. However, str...

Kalkine Media PXS 5 months ago
Dr Boreham’s Crucible: Why is Pharmaxis’ valuation so ‘pitiful’? Karst Peak doesn’t know either

Inflammatory diseases company Pharmaxis (ASX:PSX) this month welcomed a familiar biotech name to the register: Karst Peak Capital. The Hong Kong and Sydney based ‘contrarian’ fund manager is also a major holder in Neuren and Cyclopharm, and...

Stockhead PXS 5 months ago
Pharmaxis has multiple potential value inflection points with two drugs advancing in clinical trials

The clinical stage drug development company has boosted its balance sheet with a $4.4 million placement and the sale of Bronchitol Russian distribution rights for $2 million.

Proactive Investors PXS 5 months ago